HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
A phase 2 trial of Patritumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Overview
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04619004 by Daiichi Sankyo, with 277 participants enrolled, started 2021-02-02 and due to reach its primary completion in 2022-11-21. Interventions recorded: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration). Conditions listed: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Shares Daiichi Sankyo, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Shares Patritumab deruxtecan, Daiichi Sankyo.
- TrialA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Shares Patritumab deruxtecan, Daiichi Sankyo.
- TrialA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Shares Patritumab deruxtecan, Daiichi Sankyo, Non-small-cell lung cancer.
- TrialStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
Shares Daiichi Sankyo, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Patritumab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.